Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca's Ticagrelor Gets Positive EU Recommendation, But FDA Could Catch Up Soon

This article was originally published in The Pink Sheet Daily

Executive Summary

Europe's CHMP recommends ticagrelor for patients with acute coronary syndromes, while FDA still grapples with lack of effect in North American patients.

You may also be interested in...



AstraZeneca Says Brilinta Premium Pricing Merited Based On Labeling

During its quarterly earnings call, the pharma pointed out that international reimbursement decisions have supported premium pricing over Plavix.

AstraZeneca Says Brilinta Premium Pricing Merited Based On Labeling

During its quarterly earnings call, the pharma pointed out that international reimbursement decisions have supported premium pricing over Plavix.

AstraZeneca's Brilique Approved In The EU

AstraZeneca's antiplatelet agent Brilique/Brilinta receives its first approval, but pricing negotiations will delay launch in most countries.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071227

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel